Moderna and Merck's Melanoma Therapy Success Drives Stock Surge

Moderna and Merck announced that their melanoma therapy met its primary goal in a Phase 3 trial, leading to significant jumps in both companies' stock prices. Moderna's shares rocketed 93%, while Merck's rose 7% following the positive news.